Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?
Abhinav Vasudevan, Daniel R van Langenberg, Department of Gastroenterology and Hepatology, Eastern Health, Box Hill Hospital, Box Hill, Victoria 3128, Australia
Abhinav Vasudevan, Daniel R van Langenberg, Monash University, Eastern Health Clinical School, Box Hill, Victoria 3128, Australia
Peter R Gibson, Department of Gastroenterology, Alfred Health and Monash University, Victoria 3004, Australia
Author contributions: Vasudevan A and van Langenberg DR were involved in the conception of the review, acquisition of data and analysis, drafting the article and final approval of the version to be submitted; Gibson PR was involved in drafting and the critical appraisal of the article.
Conflict-of-interest statement: Vasudevan A has no conflict of interest to declare; Gibson PR has served as consultant or advisory board member for AbbVie, Ferring, Janssen, Merck, Nestle Health Science, Danone, Allergan, Pfizer, Celgene and Takeda. His institution has received speaking honoraria from AbbVie, Janssen, Ferring, Takeda, Fresenius Kabi, Mylan and Pfizer. He has received research grants for investigator-driven studies from AbbVie, Janssen, Falk Pharma, Danone and A2 Milk Company. His Department financially benefits from the sales of a digital application and booklets on the low FODMAP diet. He has published an educational/recipe book on diet. van Langenberg DR has served as a speaker and/or received travel support from Takeda, Ferring and Shire. He has consultancy agreements with Abbvie, Janssen and Pfizer. He received research funding grants for investigator-driven studies from Ferring, Shire and AbbVie.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Abhinav Vasudevan, B. Medicine, Gastroenterologist, Department of Gastroenterology and Hepatology, Eastern Health, Level 2, 5 Arnold Street, Box Hill Hospital, Box Hill, Victoria 3128, Australia. firstname.lastname@example.org
Telephone: +61-3-90949555 Fax: +61-3-98999137
Received: June 2, 2017
Peer-review started: June 6, 2017
First decision: June 22, 2017
Revised: July 3, 2017
Accepted: August 15, 2017
Article in press: August 15, 2017
Published online: September 21, 2017